Omnicell (NASDAQ:OMCL) Issues FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 1.650-1.850 for the period, compared to the consensus estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Wall Street Analysts Forecast Growth

OMCL has been the topic of several research analyst reports. Benchmark reissued a “buy” rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America lowered their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, March 24th. JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Finally, Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.01 on Friday. The company has a market cap of $1.64 billion, a P/E ratio of 129.67, a P/E/G ratio of 7.53 and a beta of 0.85. The firm’s 50 day moving average is $39.01 and its two-hundred day moving average is $42.58. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Analysts expect that Omnicell will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.